Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | GRB2 | P62993 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10143499 | 0.92 | TLR2 (0.45) | TLR2PTPN1TPSAB1HDAC4EP300 | |
| SCHEMBL10143500 | 0.89 | SIRT5 (0.42) | TLR2PTPN1GRB2SIRT5TPSAB1 | |
| SCHEMBL10143401 | 0.89 | TLR2 (0.46) | TLR2PTPN1MMP3HDAC4 | |
| SCHEMBL10144324 | 0.89 | TLR2 (0.44) | TLR2PTPN1TPSAB1HDAC4EP300 | |
| SCHEMBL10144428 | 0.88 | TLR2 (0.42) | TLR2PTPN1GRB2TPSAB1HDAC4 | |
| SCHEMBL10143497 | 0.88 | TLR2 (0.42) | TLR2PTPN1GRB2TPSAB1 | |
| SCHEMBL10144426 | 0.88 | TLR2 (0.42) | TLR2PTPN1TPSAB1HDAC4MEF2D | |
| SCHEMBL10143518 | 0.87 | TLR2 (0.43) | TLR2PTPN1GRB2TPSAB1HDAC4 | |
| SCHEMBL10144446 | 0.86 | TLR2 (0.43) | TLR2PTPN1TPSAB1HDAC4EP300 | |
| SCHEMBL10144432 | 0.82 | CA1 (0.45) | TLR2SIRT5TPSAB1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012009258-A2 | PEPTIDOMIMETIC GALANIN RECEPTOR MODULATORS | ROBERTS EDWARD (US) | 2012-01-19 | — | — | WO | disclosed |